STATEMENT OF EDITORIAL PURPOSE
The Hospital Physician Hematology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations in hematology. Each manual reviews a topic essential to the current practice of hematology.

PUBLISHING STAFF
PRESIDENT, GROUP PUBLISHER
Bruce M. White

EDITORIAL DIRECTOR
Debra Dreger

ASSOCIATE EDITOR
Rita E. Gould

ASSISTANT EDITOR
Farrawh Charles

EXECUTIVE VICE PRESIDENT
Barbara T. White

EXECUTIVE DIRECTOR
OF OPERATIONS
Jean M. Gaul

PRODUCTION DIRECTOR
Suzanne S. Banish

PRODUCTION ASSISTANT
Nadja V. Frist

ADVERTISING/PROJECT DIRECTOR
Patricia Payne Castle

SALES & MARKETING MANAGER
Deborah D. Chavis

NOTE FROM THE PUBLISHER:
This publication has been developed without involvement of or review by the American Board of Internal Medicine.

Hematopoietic Stem Cell Transplant: Review Questions

Series Editor and Contributor:
Eric D. Jacobsen, MD
Instructor of Medicine, Harvard Medical School, Boston, MA;
Attending Physician, Dana-Farber Cancer Institute, Boston, MA

Table of Contents

Questions .................................................2

Answers and Explanations ..............................5

References ..............................................10

Cover Illustration by Kathryn K. Johnson

Copyright 2008, Turner White Communications, Inc., Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications. The preparation and distribution of this publication are supported by sponsorship subject to written agreements that stipulate and ensure the editorial independence of Turner White Communications. Turner White Communications retains full control over the design and production of all published materials, including selection of topics and preparation of editorial content. The authors are solely responsible for substantive content. Statements expressed reflect the views of the authors and not necessarily the opinions or policies of Turner White Communications. Turner White Communications accepts no responsibility for statements made by authors and will not be liable for any errors of omission or inaccuracies. Information contained within this publication should not be used as a substitute for clinical judgment.
Choose the single best answer for each question.

1. A 29-year-old man presents with a 2-week history of progressive shortness of breath and dry cough but no fever. His past medical history is significant for relapsed Hodgkin lymphoma. Six months ago, the patient underwent high-dose chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous stem cell transplantation. The current physical examination is notable for bilateral basilar crackles, but the jugular venous pressure is normal. There is no edema and no evidence of a cardiac rub or gallop. The patient’s vital signs are heart rate of 72 bpm, blood pressure of 114/76 mm Hg, temperature of 98.6°F, respiratory rate of 22 breaths/min, and oxygen saturation of 90% on room air. The patient is receiving trimethoprim/sulfamethoxazole and acyclovir, both of which were started at the time of his transplant. A restaging computed tomography (CT) scan of the chest, abdomen, and pelvis performed 4 weeks prior to this visit showed only a subtle bilateral interstitial infiltrate but no evidence of disease recurrence. What is the most likely diagnosis for the patient’s symptoms?
   (A) Carmustine-induced lung injury
   (B) Congestive heart failure
   (C) *Pneumocystis jiroveci* pneumonia
   (D) Pulmonary embolism
   (E) Relapsed Hodgkin lymphoma

2. A 42-year-old man with a history of relapsed acute myelogenous leukemia (AML) underwent cyclophosphamide and total body irradiation (TBI) conditioning followed by allogeneic stem cell transplantation with a fully matched brother as his donor. Over the last 2 days, the patient’s weight has increased by 15 kg. On physical examination, he now has moderate ascites with 2+ bilateral lower extremity edema, and his liver is newly enlarged and tender to palpation. The patient is afebrile. Notable laboratory studies are listed in Table 1. The patient had no known liver disease prior to transplantation. Which is the most likely diagnosis for the patient’s symptoms?
   (A) Acute reactivation of hepatitis B
   (B) Cholangitis
   (C) Graft-versus-host disease (GVHD) of the liver
   (D) Relapsed AML
   (E) Veno-occlusive disease of the liver (VOD)

3. A 32-year-old woman who underwent allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL) 40 days ago presents for a follow-up visit. Over the last 3 visits in the last month, the platelet count has decreased from 157,000 to 25,000 cells/µL (normal, 150,000–350,000 cells/µL), and she is mildly anemic. Creatinine levels have risen from 0.6 to 2.4 mg/dL (normal, 0.6–1.2 mg/dL). The white blood cell (WBC) count is 4.7 cells/µL (normal, 4500–11,000 cells/µL), and there are no circulating blasts. A bone marrow biopsy reveals no evidence of leukemia but does show increased megakaryocytes and slightly increased red blood cell precursors. Otherwise, the patient reports feeling well with the exception of fatigue. She is taking sirolimus and tacrolimus for GVHD prophylaxis. The sirolimus level was low at the last visit, but the tacrolimus level was within therapeutic range. Which is the most likely diagnosis for the patient’s symptoms?
   (A) Chronic GVHD
   (B) Immune thrombocytopenic purpura
   (C) Relapsed ALL with a falsely negative bone marrow biopsy
   (D) Tacrolimus toxicity
   (E) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP-HUS)